GSK said Wednesday that its new Arexvy vaccine for respiratory syncytial virus pulled in 709 million pounds, or about $860 million, in its first few months on the market
The sales figures outpaced what was already a strong launch from rival Pfizer, which a day earlier announced third quarter revenue of $375 million for its Abrysvo vaccine for RSV.
